Cytokinetics falls on omecamtiv mecarbil data

Cytokinetics Inc. (NASDAQ:CYTK) fell $2.82 (27%) to $7.65 on Tuesday after it and partner Amgen Inc. (NASDAQ:AMGN) said omecamtiv mecarbil given as a 48-hour IV infusion missed the primary endpoint in the 613-patient Phase IIb ATOMIC-AHF trial to treat patients with left ventricular systolic dysfunction hospitalized for acute heart failure. Omecamtiv mecarbil did not improve dyspnea symptom response rate vs. placebo (p=0.33).

The partners said a supplemental analysis showed the highest of three omecamtiv mecarbil dose groups did significantly improve dyspnea symptom response rate vs. placebo (51% vs. 37%, p=0.03). Data were presented at the European Society of Cardiology meeting in Amsterdam. ...